Accepted Manuscript

Synovial and Systemic Pharmacokinetics of Triamcinolone Acetonide Following Intraarticular Injection of an Extended-Release Microsphere-Based Formulation (FX006) or Standard Crystalline Suspension in Patients with Knee Osteoarthritis

Virginia B. Kraus, MD PhD, Philip G. Conaghan, MBBS PhD FRACP FRCP, Hessam A. Aazami, MD, Purvi Mehra, MD CPI, Alan J. Kivitz, MD CPI, Joelle Lufkin, MPH, Jessica Hauben, BS, James R. Johnson, PhD, Neil Bodick, MD PhD

PII: S1063-4584(17)31226-8

DOI: 10.1016/j.joca.2017.10.003

Reference: YJOCA 4095

To appear in: Osteoarthritis and Cartilage


Received Date: 10 March 2017

Revised Date: 16 August 2017

Accepted Date: 1 October 2017

Please cite this article as: Kraus VB, Conaghan PG, Aazami HA, Mehra P, Kivitz AJ, Lufkin J, Hauben J, Johnson JR, Bodick N, Synovial and Systemic Pharmacokinetics of Triamcinolone Acetonide Following Intra-articular Injection of an Extended-Release Microsphere-Based Formulation (FX006) or Standard Crystalline Suspension in Patients with Knee Osteoarthritis, *Osteoarthritis and Cartilage* (2017), doi: 10.1016/j.joca.2017.10.003.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Title: Synovial and Systemic Pharmacokinetics of Triamcinolone Acetonide Following Intraarticular Injection of an Extended-Release Microsphere-Based Formulation (FX006) or Standard Crystalline Suspension in Patients with Knee Osteoarthritis

Authors: Virginia B Kraus MD PhD (kraus004@duke.edu),¹ Philip G Conaghan MBBS PhD FRACP FRCP (p.conaghan@leeds.ac.uk),² Hessam A Aazami MD (haazami@hopeclinical.com),³ Purvi Mehra MD CPI (pmehra@artemis-research.com),⁴ Alan J Kivitz MD CPI (ajkivitz@yahoo.com),⁵ Joelle Lufkin MPH (jlufkin@flexiontherapeutics.com),⁶ Jessica Hauben BS (jhauben@flexiontherapeutics.com),⁶ James R Johnson PhD (jjohnson@summitanalytical.com),⁷ Neil Bodick MD PhD (nbodick@flexiontherapeutics.com)⁶

Affiliations: ¹Duke University School of Medicine, Durham, NC, USA; ² Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK; ³Hope Clinical Research, Canoga Park, CA, USA; ⁴Artemis Institute for Clinical Research, San Diego, CA, USA; ⁵Altoona Center for Clinical Research, Duncansville, PA, USA; ⁶Flexion Therapeutics, Inc., Burlington, MA, USA; ⁷Summit Analytical, Inc., Cary, NC, USA

Corresponding author: Virginia B Kraus MD PhD, Duke University School of Medicine, PO Box 104775, Room 51-205, Carmichael Building, 300 N Duke St, Durham, NC 27701-2047; 919-681-6652 (tel), 919-684-8907 (fax), <u>kraus004@duke.edu</u> (email). **Running title:** Synovial PK of IA corticosteroids in knee OA Download English Version:

https://daneshyari.com/en/article/8741730

Download Persian Version:

https://daneshyari.com/article/8741730

Daneshyari.com